H-RLFFYRKSV^-OH

Ref. 3D-PP45819

Produktinformation

• Name: H-RLFFYRKSV^-OH
• Synonyme: NH2-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val^-OH

Beschreibung

Peptide H-RLFFYRKSV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-RLFFYRKSV^-OH include the following: A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer V Georgoulias, JY Douillard, D Khayat , C Manegold - Clinical Lung Cancer, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1525730413000624 TELOMERASE TARGETING IN CANCER R Hari Krishnan - academia.eduhttps://www.academia.edu/download/64888615/Telomerase_published_paper.pdf Modification and analysis of hTERT assoiated peptide p572 Q Quan , L Ying, Q Guanxiang - Shanghai Mian yi xue za zhi, 2004 - europepmc.orghttps://europepmc.org/article/cba/524917 Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer M Talebian Yazdi, KR Keene , PS Hiemstra - Expert review of , 2014 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/14760584.2014.862499 Novel anticancer therapeutics targeting telomerase M Ruden , N Puri - Cancer treatment reviews, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0305737212001417 Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer K Kakimi, J Nakajima, H Wada - Lung Cancer, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0169500208005606 Telomaca¹res et Telomerase: des cibles toujours pertinentes en oncologie? J Mergny , L Guittat, aca‰ Segal-Bendirdjian - Bulletin du Cancer, 2020 - hal.sciencehttps://hal.science/hal-03030331/document Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen J Hernandez, K Schoeder, SE Blondelle - European journal of , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200425134 Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2. 1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells J Hernandez, F Garcaca­a-Pons, YC Lone - Proceedings of the , 2002 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.182418399 Telomeres and cancer HC Fan , FW Chang, JD Tsai, KM Lin, CM Chen , SZ Lin - Life, 2021 - mdpi.comhttps://www.mdpi.com/2075-1729/11/12/1405 Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001 EK Vetsika , G Konsolakis, D Aggouraki - Cancer Immunology , 2012 - Springerhttps://link.springer.com/article/10.1007/s00262-011-1093-4 Telomerase-targeted cancer immunotherapy E Mizukoshi, S Kaneko - International Journal of Molecular Sciences, 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/8/1823 Insights into peptide-based vaccine design for cancer immunotherapy E Lazoura, V Apostolopoulos - Current medicinal chemistry, 2005 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2005/00000012/00000013/art00003 Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001 Eleni-Kyriaki Vetsika, Georgios DA Konsolakis, A Kotsakis , E Papadimitraki, S Christou - vaxon-biotech.euhttp://vaxon-biotech.eu/wp-content/uploads/2013/03/underdev_5_vetsika.pdf Telomerase based anticancer immunotherapy and vaccines approaches C Kailashiya, HB Sharma , J Kailashiya - Vaccine, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X17312276

• Marke: Biosynth